#USA #Ibezapolstat #Staten Island #Acurx Pharmaceuticals #CDI

Acurx Pharmaceuticals Updates on Q3 2026 Performance

Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP), a biopharmaceutical company specializing in innovative antibiotics, has recently disclosed its financial performance and behind-the-scenes activities for the third quarter of 2026. This update, shared on November 12, highlights significant advancements and milestones in the clinical development of its leading antibiotic candidate, ibezapolstat.

Key Developments in Q3 2026

During this quarter, Acurx undertook a crucial meeting with the FDA in July 2026 to discuss conducting a single pivotal Phase 3 study in acute Clostridium difficile infection (CDI). The FDA showed a positive outlook toward additional discussions regarding the ibezapolstat clinical development program, particularly following the completion of the trial referred to as IBZ-ASPIRE. This meeting underscored Acurx’s commitment to developing effective solutions for serious bacterial infections that pose life-threatening risks to patients.

As the company moves forward, they have started enrolling patients for the PATHFINDER trial, a pioneering 20-patient clinical trial focused on recurrent CDI. This trial's importance has been acknowledged by the FDA and, if successful, could dramatically enhance ibezapolstat's profile in both acute and recurrent CDI treatment contexts.

In terms of scientific partnerships, Acurx has renewed its collaboration with Leiden University Medical Center to advance the development of the DNA pol IIIC inhibitors, which could lead to groundbreaking treatments that combat Gram-positive bacteria resistant to current antibiotics. A focus on producing the first-ever 3D structure of Pol C from methicillin-resistant Staphylococcus aureus (MRSA) is also a part of this ongoing research, targeting critical clinical pathogens identified by the CDC and FDA.

Scientific Advances

A notable highlight of Q3 was a presentation from the University of Houston illustrating how ibezapolstat treatment can positively influence gut microbiome repopulation, which is vital in preventing recurrence of infections. Comparatively, the data indicated that ibezapolstat outperformed traditional treatments like vancomycin and fidaxomicin in killing harmful bacteria.

In August, the proprietary brand name for ibezapolstat was granted conditional acceptance by the FDA, paving the way for establishing a commercial identity as the company gears up for its Phase 3 trials. Additionally, Acurx received patents in Japan and Mexico that further secure its intellectual property for the DNA polymerase IIIC inhibitors, with coverage extending until June 2042.

Financial Overview

On the financial side, Acurx ended Q3 with a cash reserve of $9.7 million, reflecting a slight increase from the previous quarter. The research and development expenses rose, primarily due to costs linked to the new recurrent CDI trial program. Acurx recorded a net loss of $2.6 million for the third quarter, a rise from the net loss reported during the same period last year.

This quarter marks an important turning point for Acurx Pharmaceuticals, solidifying its footprint in the antibiotic landscape while advancing critical partnerships and clinical trials that can reshape treatment protocols for CDI. To discuss these developments further, Acurx will hold a conference call, providing in-depth insights into its operations and trajectory going forward.

Conclusion

As Acurx Pharmaceuticals continues to pioneer solutions in the field of infectious diseases, the upcoming developments in its clinical trials and partnerships will be paramount. The company is poised to transform the landscape for patients suffering from CDI and rCDI, ensuring that innovative treatments like ibezapolstat are within reach for those in need. Stakeholders and interested parties can stay informed about Acurx’s progress through their official communications and calls.